Vifor Pharma announces the launch of an investment-grade S&P credit rating coverage

Vifor Pharma is a global pharmaceuticals company whose headquarter is based in Switzerland.  Its major goal is to hold the position of a global leader in iron deficiency, nephrology, and cardio-renal therapies.

Pharmaceuticals and innovative patient-focused solutions have collaborated with Vifor Pharma over the years and stand by it. Vifor Pharma group aims to help patients around the globe suffering chronic and severe diseases lead healthier lives. The business creates, manufactures and markets precision patient care pharmaceutical product.Vifor Pharma holds the leading position in all the industries in which it operates. This consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange.

Vifor Pharma has announced that Standard & Poor’s (S&P) allocated a BBB- credit rating with a constant outlook to Vifor Pharma. Vifor Pharma’s well-established position in iron deficiency and nephrology including their strong financial position has supported the initial grade investment.

Colin Bond, Vifor Pharma’s Chief Financial Officer shared that the initial investment has played a significant role in their company’s development as a global pharmaceutical company and it will also help Vifor Pharma in executing their strategy efficiently and attaining the position of a global leader in iron deficiency, nephrology, and cardio-renal therapies.

Along with many other benefits, the S&P rating will help increase comparability and transparency for debt investors and other market participants. Furthermore, Vifor Pharma is determined to continue the investment-grade rating.

J.P Morgan has counseled Vifor Pharma during the credit rating process.